- Home
- BCDA vs SQFT Comparison
BCDA vs SQFT Comparison
Compare BCDA & SQFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCDA
- SQFT
- Stock Information
- Founded
- BCDA N/A
- SQFT 1999
- Country
- BCDA United States
- SQFT United States
- Employees
- BCDA N/A
- SQFT N/A
- Industry
- BCDA Biotechnology: Pharmaceutical Preparations
- SQFT Real Estate Investment Trusts
- Sector
- BCDA Health Care
- SQFT Real Estate
- Exchange
- BCDA Nasdaq
- SQFT Nasdaq
- Market Cap
- BCDA 10.1M
- SQFT 6.2M
- IPO Year
- BCDA N/A
- SQFT 2020
- Fundamental
- Price
- BCDA $2.39
- SQFT $5.15
- Analyst Decision
- BCDA Strong Buy
- SQFT
- Analyst Count
- BCDA 1
- SQFT 0
- Target Price
- BCDA $25.00
- SQFT N/A
- AVG Volume (30 Days)
- BCDA 230.7K
- SQFT 12.4K
- Earning Date
- BCDA 08-12-2025
- SQFT 08-13-2025
- Dividend Yield
- BCDA N/A
- SQFT N/A
- EPS Growth
- BCDA N/A
- SQFT N/A
- EPS
- BCDA N/A
- SQFT N/A
- Revenue
- BCDA $3,000.00
- SQFT $18,260,398.00
- Revenue This Year
- BCDA N/A
- SQFT $23.63
- Revenue Next Year
- BCDA N/A
- SQFT N/A
- P/E Ratio
- BCDA N/A
- SQFT N/A
- Revenue Growth
- BCDA N/A
- SQFT N/A
- 52 Week Low
- BCDA $1.63
- SQFT $4.19
- 52 Week High
- BCDA $4.66
- SQFT $8.77
- Technical
- Relative Strength Index (RSI)
- BCDA 58.67
- SQFT 51.05
- Support Level
- BCDA $1.98
- SQFT $4.55
- Resistance Level
- BCDA $2.45
- SQFT $5.77
- Average True Range (ATR)
- BCDA 0.17
- SQFT 0.37
- MACD
- BCDA 0.04
- SQFT 0.09
- Stochastic Oscillator
- BCDA 88.00
- SQFT 56.96
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About SQFT Presidio Property Trust Inc.
Presidio Property Trust Inc is an internally managed, diversified REIT with holdings in model home properties which are triple-net leased to homebuilders, office, industrial, and retail properties. Presidio's model homes are leased to homebuilders located in Arizona, Illinois, Texas, Wisconsin, and Florida. The office, industrial and retail properties are located in Colorado, with properties also located in Maryland, North Dakota, Texas, and Southern California.